Alwin Krämer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alwin Krämer has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Harald Löffler
German Cancer Research Center (DKFZ) and University of Heidelberg
5 shared publications Harald Löffler
Clinical Cooperation Unit Molecular Hematology/Oncology; German Cancer Research Center (DKFZ) and Department of Internal Medicine V; University of Heidelberg; Heidelberg, Germany
3 shared publications- Jiri Lukas
Protein Signaling Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications Anthony D. Ho
University of Heidelberg; Heidelberg, Germany
2 shared publicationsGonzalo Durán-Pacheco
Global Product Development Medical Affairs, F Hoffmann-La Roche, Basel, Switzerland
2 shared publicationsJiri Bartek
Danish Cancer Society; Copenhagen, Denmark
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 31 July 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10452) , 527-539
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
- 31 July 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10452) , 527-539
Top Cited PapersOpen AccessMolecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
- Open Access
- 4 August 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 194, 113278
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
- 4 August 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 194, 113278
Open AccessModified study designs to expand treatment options in personalised oncology: a multistakeholder view
- Open Access
- 25 June 2023
- Published by Elsevier in STAR Protocols
- Vol. 4 (3) , 102373
Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
- 25 June 2023
- Published by Elsevier in STAR Protocols
- Vol. 4 (3) , 102373
Open AccessProtocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
- Open Access
Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
Knowledge of contemporary patterns of cancer-of-unknown-primary-origin (CUP) diagnostic work-up, treatment, and outcomes in routine healthcare is limited. Thus, we examined data from elderly patients diagnosed with CUP in real-world US clinical practice. From the Surveillance, Epidemiology, and End Results–Medicare-linked database, we included patients ≥ 66 years old with CUP diagnosed between 1 January 2013 and 31 December 2015. We analyzed baseline demographics, clinical characteristics, methods of diagnostic work-up (biopsy, immunohistochemistry, imaging), treatment-related factors, and survival. CUP diagnosis was histologically confirmed in 2813/4562 patients (61.7%). Overall, 621/4562 (13.6%) patients received anticancer pharmacotherapy; among these, 97.3% had a histologically confirmed tumor and 83.1% received all three procedures. Among those with a histologically confirmed tumor, increasing age, increasing comorbidity score, not receiving all three diagnostic measures, and having a not-further specified histologic finding of only ‘malignant neoplasm’ were all negatively associated with receipt of anticancer pharmacotherapy. Median overall survival was 1.2 months for all patients. Median time between CUP diagnosis and treatment initiation was 41 days. Limited diagnostic work-up was common and most patients did not receive anticancer pharmacotherapy. The poor outcomes highlight a substantial unmet need for further research into improving diagnostic work-up and treatment effectiveness in CUP.
Open AccessCancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
Knowledge of contemporary patterns of cancer-of-unknown-primary-origin (CUP) diagnostic work-up, treatment, and outcomes in routine healthcare is limited. Thus, we examined data from elderly patients diagnosed with CUP in real-world US clinical practice. From the Surveillance, Epidemiology, and End Results–Medicare-linked database, we included patients ≥ 66 years old with CUP diagnosed between 1 January 2013 and 31 December 2015. We analyzed baseline demographics, clinical characteristics, methods of diagnostic work-up (biopsy, immunohistochemistry, imaging), treatment-related factors, and survival. CUP diagnosis was histologically confirmed in 2813/4562 patients (61.7%). Overall, 621/4562 (13.6%) patients received anticancer pharmacotherapy; among these, 97.3% had a histologically confirmed tumor and 83.1% received all three procedures. Among those with a histologically confirmed tumor, increasing age, increasing comorbidity score, not receiving all three diagnostic measures, and having a not-further specified histologic finding of only ‘malignant neoplasm’ were all negatively associated with receipt of anticancer pharmacotherapy. Median overall survival was 1.2 months for all patients. Median time between CUP diagnosis and treatment initiation was 41 days. Limited diagnostic work-up was common and most patients did not receive anticancer pharmacotherapy. The poor outcomes highlight a substantial unmet need for further research into improving diagnostic work-up and treatment effectiveness in CUP.
- 1 May 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 402 (1) , 112566
The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia
- 1 May 2021
- Published by Elsevier in Experimental Cell Research
- Vol. 402 (1) , 112566
The JmjC-domain protein NO66/RIOX-1 affects the balance between proliferation and maturation in acute myeloid leukemia
- 13 February 2020
- Published by Springer Nature in best practice onkologie
- Vol. 15 (3) , 76-84
Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
- 13 February 2020
- Published by Springer Nature in best practice onkologie
- Vol. 15 (3) , 76-84
Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
- 16 October 2019
- Published by Springer Nature in Forum
- Vol. 34 (6) , 559-560
Karzinome mit unklarer Primärlokalisation – CheCUP‑Studie
- 16 October 2019
- Published by Springer Nature in Forum
- Vol. 34 (6) , 559-560
Karzinome mit unklarer Primärlokalisation – CheCUP‑Studie
- 1 January 2016
- Published by Springer Nature
- p. 191-194
Future Directions